MOUNJARO® 12.5mg KwikPen®, 1 Stk.

MOUNJARO® 12.5mg KwikPen is an injection in a pre-filled pen containing tirzepatide — the active substance — at a strength of 12.5mg per 0.6ml dose, manufactured by Eli Lilly and Company Limited.[1][5] Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated for patients with type 2 diabetes mellitus and, in markets where MOUNJARO® carries the weight management indication, for eligible adults as an adjunct to diet and exercise.[4][5] The 12.5mg dose is the high-dose titration or maintenance step immediately below the maximum 15 mg of tirzepatide in the approved escalation schedule, with each KwikPen delivering four once-weekly subcutaneous doses.[1][5] Looking to buy MOUNJARO® 12.5mg KwikPen online? Licensed professionals are encouraged to contact Medica Depot’s support representatives for product and ordering guidance.

Product Specifications

What is MOUNJARO® 12.5mg KwikPen?

Tirzepatide is the international non-proprietary name (INN) of the active substance; MOUNJARO® is the proprietary brand name Eli Lilly uses for it across applicable markets and strengths.[1][5] MOUNJARO® is therefore tirzepatide, and tirzepatide is the same molecule present in every MOUNJARO® presentation from 2.5mg through 15mg — the names describe the same therapeutic agent, though they are not interchangeable regulatory designations in every jurisdiction.[5] In the U.S., tirzepatide is marketed as MOUNJARO® for type 2 diabetes and as Zepbound® for chronic weight management; in the EU and certain other international markets, MOUNJARO® covers both indications under a single brand.[4][5]

The 12.5 mg dose occupies the penultimate position in the MOUNJARO® titration schedule — a high-dose titration or maintenance strength, one step below the maximum 15 mg of tirzepatide — and is prescribed once patients have established tolerability to 10mg for at least four weeks.[1][5] It is the strength at which near-maximum glycemic and metabolic efficacy is approached, making clinical monitoring of tolerability and patient response at this step important before any decision to escalate further.[1]

The KwikPen is a single-patient-use, multi-dose pre-filled device delivering four fixed once-weekly subcutaneous doses of 12.5mg tirzepatide per 0.6ml injection.[1][5] When buying online, licensed professionals should confirm which presentation is appropriate for the relevant market and procurement channel. Professionals reviewing their options may contact Medica Depot’s support representatives or explore how to buy MOUNJARO® through appropriate licensed channels.

Mechanism of Action and Pharmacology

Tirzepatide is a synthetic acylated peptide that independently activates both the GIP and GLP-1 receptors through distinct binding interactions[1][5]. This dual mechanism drives complementary pathways, underpinning its distinct glycemic and weight-reduction profile[1].

• GLP-1 Pathway: Stimulates glucose-dependent insulin secretion, suppresses glucagon release during hyperglycemia, and delays gastric emptying—reducing fasting and postprandial glucose[1][5].
• GIP Pathway: Synergistically augments insulin secretion and modulates adipose tissue lipid metabolism[1]. GIP activation may also attenuate GLP-1-associated gastrointestinal side effects, though this contribution is still being characterized[1].

Because both pathways are glucose-dependent, monotherapy carries a low intrinsic risk of hypoglycemia[1][5]. However, the risk increases substantially when MOUNJARO® is combined with insulin or sulfonylureas [1][5].

The SURPASS-1 phase 3 trial demonstrated significant reductions in HbA1c and weight versus placebo, with consistent efficacy across gender, race, and ethnicity subgroups [1][4]. The 12.5mg dose approaches near-maximum efficacy across the dose range[1][4]. GI adverse events remain dose-dependent[1][4]. In the SURPASS-CVOT trial, tirzepatide met its primary endpoint of non-inferiority to dulaglutide for MACE-3, though it lacks an FDA-approved MACE-reduction indication in the U.S.[2] Post hoc cardiorenal analyses examined outcomes beyond the primary MACE endpoint in patients with concurrent cardiovascular and renal risk [3].

No dose adjustment is required for mild-to-moderate renal or hepatic impairment[5]. Experience in severe impairment is limited; caution is advised, and prescribers should review the full prescribing information before use[5].

Indications and Patient Selection

Regional labeling governs approved indications. Prescribers must confirm local jurisdictional scope before initiating therapy.

• Type 2 Diabetes (U.S. & EU): Indicated as an adjunct to diet and exercise for adults and pediatric patients aged 10 and older[4][5]. Approved as monotherapy (if metformin is inappropriate) or combined with other antidiabetic agents[4][5]. Crucial Note: The pediatric maximum dose is capped at 10mg weekly in both regions; therefore, the 12.5mg strength is strictly restricted to adults [5]. It is not indicated for Type 1 diabetes and must not be used as a substitute for insulin [5].
• Chronic Weight Management (EU Only): Indicated as an adjunct to diet and exercise for adults with a BMI ≥30 kg/m², or ≥27 kg/m² to <30 kg/m² with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes)[5]. This indication does not apply to MOUNJARO® in the U.S., where weight management is marketed as Zepbound® [5].
• Cardiovascular Outcomes: MOUNJARO® lacks an FDA-approved MACE-reduction indication in the U.S. However, SURPASS-CVOT demonstrated non-inferiority to dulaglutide for MACE-3, providing relevant clinical signals for patients with type 2 diabetes and established cardiovascular disease[2][3].

Patient Selection at 12.5mg

The 12.5mg dose is for patients who have tolerated 10mg for at least 4 weeks but require further glycemic or weight optimization before escalating to the maximum 15mg strength [1][5]. Subgroup analyses confirm consistent efficacy across gender, race, and ethnic lines [1][4].

Before initiating the 12.5mg dose, prescribers must evaluate:

• Renal & Hepatic Status: Assess for impairment, especially if severe GI events have caused volume depletion[5].
• Concomitant Medications: Evaluate concurrent sulfonylureas or basal insulin (SURPASS-5). Consider a stepwise dose reduction of these partner agents to mitigate the elevated risk of hypoglycemia [5].

Administration and How to Use MOUNJARO® 12.5mg KwikPen

MOUNJARO® 12.5mg KwikPen is administered as a once-weekly subcutaneous injection at any time of day, independently of meals[1][5].

• Missed Doses: If missed, administer as soon as possible within 4 days (96 hours). If more than 4 days pass, skip the dose and resume the regular weekly schedule. Never double dose[5].
• Organ Impairment: No dose adjustment is required for mild-to-moderate renal or hepatic impairment. Maintain adequate hydration to prevent volume depletion due to GI side effects; use caution in severe impairment [5].

Injection Protocol & Technique

• Preparation & Inspection: Inspect the solution before use. It must be clear and colorless-to-slightly-yellow; discard if cloudy, discolored, or containing particulates. Attach a new needle for each injection according to the manufacturer’s instructions[5].
• Site Selection: Inject subcutaneously into the abdomen, thigh, or outer upper arm (if administered by another person). Rotate sites weekly and avoid areas with bruising, scars, or lipohypertrophy. Note: Because 12.5mg exceeds the pediatric maximum dose, this strength is for adult use only[5].
• Delivery: Fully press the activation button and hold it for 10 seconds to ensure the dose is delivered. Verify that the dose window has advanced before withdrawing the pen, then discard the used needle safely[5].

Insulin Co-administration Warning: When used alongside basal insulin, blood glucose self-monitoring is required—especially during titration to 12.5mg[5]. Do not mix both products in the same syringe or inject into adjacent sites within the same body region. Use stepwise insulin dose reduction if hypoglycemia occurs [5].

Side Effects and Safety Profile

The 12.5mg adverse profile matches the GLP-1/GIP class, though gastrointestinal (GI) event rates are dose-dependent and occur more frequently than at lower titration steps[1][4].

• Common GI Events: Nausea, diarrhea, vomiting, abdominal pain, constipation, decreased appetite, and dyspepsia[1][4][5]. These are typically mild-to-moderate, peak during dose escalation, and attenuate over time[1][4].
• Severe GI Disease: MOUNJARO® has not been studied in severe gastroparesis; use with caution[5].
• Injection Site Reactions: Localized redness, pruritus, or swelling may occur. Minimize by rotating sites weekly[5].

Serious Risks & Monitoring

• Hypoglycemia: Risk rises significantly when combined with insulin or sulfonylureas. Blood glucose self-monitoring is required; consider a stepwise dose reduction of the partner agent[5].
• Pancreatitis: Acute pancreatitis has been reported. Discontinue permanently if suspected or confirmed[5].
• Gallbladder & Renal Risks: Cholelithiasis and cholecystitis may occur. Dehydration from GI side effects can precipitate acute kidney injury; counsel patients on strict hydration[5].
• Diabetic Retinopathy: Rapid glycemic changes may transiently worsen retinopathy; monitor patients with pre-existing conditions closely [5].
• Pulmonary Aspiration: Delayed gastric emptying increases residual gastric volume. Consider this risk prior to procedures that require general anesthesia or deep sedation [5].

Boxed Warning & Contraindications: MOUNJARO® carries a U.S. boxed warning for thyroid C-cell tumors[5]. It is strictly contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or known hypersensitivity[5].

Legal Status and Professional Use

MOUNJARO® (tirzepatide) is a prescription-only pharmaceutical manufactured by Eli Lilly and Company Limited. In the United States, it received initial FDA approval on May 13, 2022, for type 2 diabetes mellitus in adults and, following label updates, in pediatric patients aged 10 years and older; the 12.5mg dose is part of the approved adult titration schedule.[4][5] Chronic weight management in the U.S. is addressed by Zepbound® (tirzepatide), not by MOUNJARO®.[5]

In the European Union, MOUNJARO® received initial marketing authorization on September 15, 2022, for type 2 diabetes in adults; the weight management indication for adults was added in November 2023; the multi-dose KwikPen presentation received European Commission authorization for both indications on April 19, 2024; and a further variation extending the type 2 diabetes indication to adolescents and children aged 10 years and above received a positive CHMP opinion on December 11, 2025. The EU marketing authorization holder is Eli Lilly Nederland B.V. Prescribers outside the EU should confirm with the relevant regulatory authority whether the 12.5mg strength is approved in the target jurisdiction.

MOUNJARO® is restricted to licensed medical professionals across all markets.[4][5] Prescribers and procurement teams should verify the current approved indications, prescribing requirements, and supply chain compliance in their jurisdiction. Professionals wishing to buy MOUNJARO® KwikPen wholesale or check for wholesale buying options for their practice or facility are encouraged to contact Medica Depot’s support representatives directly. Information on this page reflects publicly available data current as of the date of publication and is subject to change.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

1. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021. https://pubmed.ncbi.nlm.nih.gov/34186022/
2. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine. 2025. https://www.nejm.org/doi/10.1056/NEJMoa2505928
3. Nissen SE, Wolski K, D’Alessio D, et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiology. 2026. https://jamanetwork.com/journals/jamacardiology/fullarticle/2847048
4. U.S. Food and Drug Administration. Drug Trials Snapshots: MOUNJARO. FDA. 2023. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-mounjaro
5. Eli Lilly and Company. MOUNJARO® (tirzepatide) U.S. Prescribing Information. https://pi.lilly.com/us/mounjaro-uspi.pdf